Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR) - Lee, Jin Soo; Manegold, Christian (Journal of clinical oncology, 2012)
Gesehen am 11.04.2018